Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
Cerebrolysin is not a single peptide, and this single fact reframes everything about how to think about the compound. It is a proprietary porcine brain-derived extract manufactured by EVER Neuro Pharma (Austria) since the early 1970s. The preparation consists of a heterogeneous mixture of low-molecular-weight neuropeptides and free amino acids produced by controlled enzymatic hydrolysis of purified pig brain tissue. Recent NanoLC-MS analytical characterization (Yang et al. 2023, Journal of Chromatography B) has identified the active peptide constituents as a complex mixture of short-chain peptides, but the exact composition remains proprietary and the active components have not been fully characterized.
Cerebrolysin has the largest evidence base of any peptide-based neurological therapy with over 500 PubMed-indexed studies spanning 50 years of clinical and preclinical research. The compound is approved in over 50 countries across Europe, Middle East, Latin America, Asia, and post-Soviet states for acute ischemic stroke (most common indication), traumatic brain injury (TBI), Alzheimer's disease and dementia, vascular dementia, and cognitive impairment of various etiologies.
However, Cerebrolysin is NOT approved in the United States, United Kingdom, or Australia, and the evidence base is genuinely contested. Industry-sponsored RCTs have generally shown positive results, but multiple Cochrane reviews across three decades have consistently found insufficient evidence for routine clinical use due to study heterogeneity, risk of bias, and lack of independent confirmation. This creates a notable disconnect between widespread international clinical use and Western academic neurological caution.
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| **IV infusion** (Cerebrolysin, primary route) | Mixture; component-specific PK (multiple peptide fragments + free amino acids each with own profile) |
| **IM injection** (alternative parenteral route) | Mixture; component-specific PK |
What it does
Main effects
- Acute ischemic stroke recovery: most common indication; CASTA trial (1,070 patients, improved 90-day cognitive outcomes); CARS trial (Muresanu et al. 2016, PMID 26564102); positive industry-sponsored meta-analyses
- Traumatic brain injury: improved cognitive recovery and functional outcomes in industry-sponsored trials
- Alzheimer's disease and dementia: Alvarez et al. trials showed cognitive and global function improvements; combination with donepezil showed benefits over donepezil alone
- Vascular dementia: among the strongest evidence bases for this indication; multiple Phase 3 trials
- Cognitive impairment of various etiologies
- Multi-factorial neurotrophic-like mechanism: proposed mimicry of BDNF, NGF, GDNF, CNTF activity via low-MW peptide fragments crossing BBB; recent independent (2024) in-vitro study replicated BDNF upregulation
- Mitigation of multiple steps in the ischemic cascade: excitotoxicity reduction, calcium homeostasis preservation, oxidative stress reduction, anti-inflammatory effects, anti-apoptotic effects, neurotrophic support of penumbra
- Possible neurogenesis support: dentate gyrus neurogenesis, neural progenitor proliferation
- Synaptic plasticity enhancement: LTP effects in some studies
- Approved in 50+ countries with 50+ years of continuous clinical use
What to watch for
Common side effects
- NOT a single peptide: proprietary porcine brain-derived heterogeneous mixture (~15% peptides <10 kDa, ~85% free amino acids); manufactured exclusively by EVER Neuro Pharma since the early 1970s; this fundamentally distinguishes Cerebrolysin from every other peptide in this library
- NOT FDA-approved (US, UK, Australia): major Western markets have not approved despite 50+ country approvals elsewhere
- Evidence is genuinely contested: positive industry-sponsored RCTs vs persistently skeptical Cochrane reviews across three decades (2010, 2013, 2020, 2023)
- 2023 Cochrane review for acute ischemic stroke (PMID 37818733): "Moderate-certainty evidence indicates that Cerebrolysin or Cerebrolysin-like peptide mixtures derived from cattle brain probably have no beneficial effect on preventing all-cause death" and indicated "potential increase in non-fatal serious adverse events", a substantially negative independent assessment
- Industry-sponsorship dominance: most positive evidence comes from EVER Neuro Pharma-sponsored research; independent replication is limited
- Porcine origin = absolute contraindication for anyone with pork allergy or religious dietary restrictions (Jewish, Muslim, others)
- Theoretical prion concerns: addressed by manufacturer quality controls; no documented transmission in 50+ years but conservative Western regulatory approach contributes to non-approval
- IV infusion or IM injection required: administered by qualified personnel in clinical settings; not self-administered
- Mild injection/infusion site reactions: common but generally mild
- Sensation of heat or sweating during infusion: common but mild
- Mild headache, dizziness, GI symptoms: occasional
- Hypersensitivity reactions possible with porcine-derived product; rare anaphylactoid reactions reported
- Rare seizure reports: causality not established; caution in patients with epilepsy or TBI
- Contraindications: porcine allergy, status epilepticus, severe renal impairment (relative), pregnancy/lactation (limited data)
- Caution with serotonergic antidepressants and MAO inhibitors
- Counterfeit Cerebrolysin documented in Western markets where the approved product isn't available
- Composition is mixture-defined, not chemically defined: exact active constituents incompletely characterized despite 2023 NanoLC-MS work (Yang et al.)
Key facts
Key facts worth knowing
- Cerebrolysin is a proprietary porcine brain-derived peptide extract manufactured exclusively by EVER Neuro Pharma in Austria. It is NOT a single peptide, distinguishing it from compounds like Semax, Selank, Sermorelin, and other research peptides covered elsewhere in this library.
- Composition: Low-molecular-weight neuropeptides (typically <10 kDa) and free amino acids derived from enzymatic breakdown of purified porcine brain proteins. Approximately 15% by mass is peptides; 85% is free amino acids and lower molecular weight constituents.
- Mechanism is proposed to mimic endogenous neurotrophic factors: particularly BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor), GDNF (glial-derived neurotrophic factor), and CNTF (ciliary neurotrophic factor). The peptide fragments cross the blood-brain barrier and provide neurotrophic-like activity without requiring full protein structures.
- Approved in 50+ countries with continuous clinical use since the early 1970s. Major markets include Russia, China, Eastern Europe, Middle East, Latin America, and many Asian countries. NOT approved in US, UK, or Australia. Major Western markets have not approved Cerebrolysin despite the substantial international evidence base.
- Substantial Phase 3 evidence: CASTA trial (1,070 stroke patients, improved 90-day cognitive outcomes); CARS trial (Muresanu et al. 2016); multiple Alzheimer's trials (improvements in cognitive and global function scales); vascular dementia trials. PMID: 26564102
- Cochrane reviews are skeptical: 2010 vascular dementia review (inconsistent results), 2013 update (Chen et al., limited evidence), 2020 update, 2023 acute ischemic stroke review: "Moderate-certainty evidence indicates that Cerebrolysin or Cerebrolysin-like peptide mixtures derived from cattle brain probably have no beneficial effect on preventing all-cause death" and indicated "potential increase in non-fatal serious adverse events." PMID: 37818733
- 2023 analytical characterization (Yang et al., Journal of Chromatography B) used NanoLC-MS to identify active peptide constituents, marking the first detailed modern characterization. 2024 independent BDNF research (Cureus in-vitro study) confirmed BDNF upregulation as one mechanism, providing supplementary evidence beyond industry-sponsored research.
- Industry-sponsored research dominance: Most positive trial evidence comes from EVER Neuro Pharma-sponsored research. Independent replication is limited. Several systematic review authors have declared ties to EVER Neuro Pharma.
- Porcine origin = absolute contraindication for anyone with pork allergy or religious dietary restrictions. Also requires consideration of theoretical concerns about prion transmission (extensively addressed by manufacturer through quality controls). Generally favorable safety profile in clinical use over 50 years. WADA status: Not currently on the WADA Prohibited List.
Legal status
Legal status
Approved in 50+ countries for stroke, TBI, dementia, and cognitive impairment. NOT approved in US, UK, Australia. Available internationally through pharmaceutical channels in approved countries. Imported through grey-market channels in non-approved countries. Not a controlled substance. Not WADA-prohibited.